rovalpituzumab tesirine
mAbexperimentalADC
Rovalpituzumab tesirine (Rova-T) is an experimental antibody-drug conjugate targeting the protein DLL3 on tumor cells. It was originally developed by Stemcentrx and was purchased by AbbVie. It was tested for use in small-cell lung cancer, but development was terminated after unsuccessful phase III trial. — Wikipedia
Clinical trial activity
12 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
6
Phase 2
7
Phase 3
3
Phase 4
0
Earliest trial started Jul 1, 2013 (NCT01901653)
Timeline
Indications
Mechanism of action
- Delta-like protein 3BINDING AGENT
Delta-like protein 3 binding agent
- DNACROSS-LINKING AGENT
DNA cross-linking agent
- DNADISRUPTING AGENT
DNA disrupting agent
- Delta-like protein 3INHIBITOR
DLL3 inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
- Payload
- tesirine
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaRovalpituzumab tesirine ↗
- ChEMBLCHEMBL3990011 ↗
Also known as
- rovalpituzumab tesirine
- rovalpituzumab tesirine
- rovalpituzumab tesirine
- sc16ld6.5
- sc16ld6.5
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03543358 | Phase 2 | Sep 10, 2018 | AbbVie |
| NCT03334487 | Phase 3 | Mar 15, 2018 | AbbVie |
| NCT03086239 | Phase 1 | May 10, 2017 | AbbVie |
| NCT03026166 | Phase 1 | Apr 13, 2017 | AbbVie, Bristol-Myers Squibb |
| NCT03061812 | Phase 3 | Apr 11, 2017 | AbbVie |
| NCT03033511 | Phase 3 | Feb 7, 2017 | AbbVie |
| NCT02819999 | Phase 1 | Oct 1, 2016 | Stemcentrx |
| NCT02874664 | Phase 1 | Sep 1, 2016 | Stemcentrx |
| NCT02709889 | Phase 1/Phase 2 (Phase 2) | Sep 1, 2016 | Stemcentrx |
| NCT02674568 | Phase 2 | Mar 8, 2016 | Stemcentrx |
| NCT01901653 | Phase 1/Phase 2 (Phase 2) | Jul 1, 2013 | SCRI Development Innovations, Stemcentrx |
| NCT03503890 | N/A | — | AbbVie |
Showing 12 of 12 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AbbVie | For profit | 7 | 7 | 4 | 2017 |
| Stemcentrx | For profit | 5 | 5 | 2 | 2013 |
| Bristol-Myers Squibb | For profit | 1 | 0 | 1 | 2017 |
| SCRI Development Innovations | For profit | 1 | 0 | 1 | 2013 |
4 organizations
Page 1 / 1